4-溴-3-碘吡啶 | 89167-20-4

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-溴-3-碘吡啶
• 英文名称: 4-bromo-3-iodopyridine
• CAS: 89167-20-4
• 化学式: C₅H₃BrIN
• 分子量: 283.894
• InChiKey: KDWZDHRURBJEIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-3-iodopyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-3-iodopyridine
CAS number: 89167-20-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H3BrIN
Molecular weight: 283.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-3-碘吡啶 在 bis-triphenylphosphine-palladium(II) chloride 、 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 copper(l) iodide 、 三乙胺 、 三苯基膦 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 4.0h， 生成 3-{2-[1-(difluoromethyl)cyclopropyl]ethynyl}-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
  参考文献：
  名称：

  [EN] BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER
  [FR] COMPOSÉS BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER

  摘要：

  本公开提供化学实体（例如，化合物或药学上可接受的盐，和/或水合物，和/或共晶体，和/或药物组合物），其抑制表皮生长因子受体（EGFR，ERBB1）和/或人类表皮生长因子受体2（HER2，ERBB2）。这些化学实体是有用的，例如，用于治疗某种疾病或疾病，其中增加（例如，过度）EGFR和/或HER2激活有助于病理和/或症状和/或疾病或疾病的进展（例如，癌症）在受试者（例如，人类）中。本公开还提供包含相同化学实体的组合物以及使用和制备相同的方法。

  公开号：

  WO2022072634A1

文献信息

• 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
  申请人：DUK SAN NEOLUX CO., LTD. 덕산네오룩스 주식회사(120150011099) Corp. No ▼ 161511-0176036BRN ▼312-86-74729

  公开号：KR20180128292A

  公开（公告）日：2018-12-03

  화학식 1로 표시되는 화합물과, 제1전극, 제2전극 및 제1전극과 제2전극 사이의 유기물층을 포함하는 유기전기소자 및 이를 포함하는 전자장치가 개시되며, 유기물층에 화학식 1로 표시되는 화합물을 포함됨으로써, 유기전기소자의 구동전압을 낮출 수 있고, 발광효율 및 수명을 향상시킬 수 있다.

  含有化学式1的化合物，以及包括第一电极、第二电极和第一电极与第二电极之间的有机物层的有机电子器件和包括该有机物层的电子装置被揭示，通过在有机物层中包括具有化学式1的化合物，可以降低有机电子器件的驱动电压，并提高发光效率和寿命。
• Synthesis and physical properties of triptycene-based oligo(p-phenyleneethynylene)s
  作者：Fei Zeng、Lin-Li Tang、Xiao-Ming Chen、Man-Hua Ding

  DOI：10.1016/j.tet.2018.10.011

  日期：2018.11

  A series of symmetrical and unsymmetrical triptycene-based oligo(op-phenyleneethynylene)s were synthesized by deprotection of the acetone protected terminal alkynes, followed by Sonogashira coupling reactions. The photophysical properties of triptycene-based OPEs both in solution and solid state have been investigated by UV–Vis and fluorescence spectroscopy. Interestingly, the obtained compounds show

  通过脱保护丙酮保护的末端炔烃，然后进行Sonogashira偶联反应，合成了一系列对称和不对称的基于三茂铁的低聚（对亚苯基乙炔基）。通过紫外线-可见光和荧光光谱研究了基于三萜烯的OPEs在溶液和固态下的光物理性质。有趣的是，所获得的化合物在固态下显示出强荧光且部分具有较高的量子产率，这表明三并茂部分不仅防止了分子间聚集，而且在固态下增强了OPEs骨架的共面性。
• Highly phosphorescent organopalladium(<scp>ii</scp>) complexes with metal–metal-to-ligand charge-transfer excited states in fluid solutions
  作者：Jinqiang Lin、Chao Zou、Xiaobao Zhang、Qin Gao、Sa Suo、Qihang Zhuo、Xiaoyong Chang、Mo Xie、Wei Lu

  DOI：10.1039/c9dt02525a

  日期：——

  pincer-type cyclometalated Pd(II) complexes with foldable diacetylide ligands show crystallographically determined intramolecular Pd⋯Pd contacts of 3.203–3.380 Å. In deoxygenated fluid solutions, these Pd(II) complexes are highly phosphorescent in the red region with emission quantum yields up to 48%, which has been ascribed to metal–metal-to-ligand charge-transfer (MMLCT) excited states in nature.

  具有可折叠的二乙炔配体的双核钳型环金属化Pd（II）配合物在晶体学上确定为3.203-3.380Å的分子内Pd⋯Pd接触。在脱氧流体溶液中，这些Pd（II）配合物在红色区域具有很高的磷光性，发射量子产率高达48％，这自然归因于金属-金属到配体的电荷转移（MMLCT）激发态。
• ALDOSTERONE SYNTHASE INHIBITORS
  申请人：BALESTRA Michael

  公开号：US20140323468A1

  公开（公告）日：2014-10-30

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 . R 3 , R 4 , R 5 , R 6 , R 7 , W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式（I）的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、W、Y、m和n的定义如本文所述。本发明还涉及包括这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• Aldosterone synthase inhibitors
  申请人：Balestra Michael

  公开号：US09181272B2

  公开（公告）日：2015-11-10

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及以下式(I)的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、W、Y、m和n如本文所定义。本发明还涉及包含这些化合物的制药组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及在这些过程中有用的中间体。